Anders Österborg

15.8k total citations
204 papers, 7.5k citations indexed

About

Anders Österborg is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Anders Österborg has authored 204 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Genetics, 112 papers in Immunology and 71 papers in Pathology and Forensic Medicine. Recurrent topics in Anders Österborg's work include Chronic Lymphocytic Leukemia Research (109 papers), Lymphoma Diagnosis and Treatment (71 papers) and Immunodeficiency and Autoimmune Disorders (44 papers). Anders Österborg is often cited by papers focused on Chronic Lymphocytic Leukemia Research (109 papers), Lymphoma Diagnosis and Treatment (71 papers) and Immunodeficiency and Autoimmune Disorders (44 papers). Anders Österborg collaborates with scholars based in Sweden, United States and Germany. Anders Österborg's co-authors include Håkan Mellstedt, Jeanette Lundin, Mahmood Jeddi‐Tehrani, Matti Aapro, Eva Kimby, Qing Yi, Marzia Palma, Lotta Hansson, A. Courdi and Pierre Soubeyran and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Anders Österborg

202 papers receiving 7.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Anders Österborg 3.2k 2.7k 2.5k 2.2k 2.1k 204 7.5k
Eva Kimby 2.5k 0.8× 4.0k 1.5× 4.9k 1.9× 2.8k 1.3× 1.1k 0.5× 203 7.7k
Alessandro Pileri 1.9k 0.6× 1.6k 0.6× 2.4k 0.9× 3.2k 1.4× 4.1k 1.9× 335 8.2k
Steven Le Gouill 1.2k 0.4× 1.7k 0.6× 3.7k 1.5× 3.3k 1.5× 1.7k 0.8× 312 7.2k
Dominique Bordessoule 1.1k 0.3× 1.9k 0.7× 2.3k 0.9× 2.2k 1.0× 2.3k 1.1× 188 6.3k
Grzegorz S. Nowakowski 1.2k 0.4× 1.6k 0.6× 3.3k 1.3× 3.4k 1.5× 775 0.4× 346 6.3k
Timothy G. Call 2.2k 0.7× 4.0k 1.5× 3.4k 1.3× 1.1k 0.5× 862 0.4× 221 5.8k
Jorge J. Castillo 1.6k 0.5× 3.8k 1.4× 5.0k 2.0× 3.3k 1.5× 1.5k 0.7× 373 8.0k
David A. Rizzieri 1.6k 0.5× 1.6k 0.6× 916 0.4× 2.5k 1.1× 4.3k 2.0× 309 8.1k
Michele Ghielmini 1.5k 0.5× 3.1k 1.1× 6.5k 2.6× 4.5k 2.0× 696 0.3× 134 8.8k
Pellegrino Musto 1.3k 0.4× 2.4k 0.9× 1.6k 0.6× 3.5k 1.6× 5.6k 2.6× 386 9.7k

Countries citing papers authored by Anders Österborg

Since Specialization
Citations

This map shows the geographic impact of Anders Österborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Österborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Österborg more than expected).

Fields of papers citing papers by Anders Österborg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Österborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Österborg. The network helps show where Anders Österborg may publish in the future.

Co-authorship network of co-authors of Anders Österborg

This figure shows the co-authorship network connecting the top 25 collaborators of Anders Österborg. A scholar is included among the top collaborators of Anders Österborg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Österborg. Anders Österborg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hedberg, Pontus, Fredrik Kahn, Åsa Nilsdotter‐Augustinsson, et al.. (2025). Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era. Blood Advances. 9(13). 3170–3181. 1 indexed citations
2.
Andersson, Maria, Jinghua Wu, David Wullimann, et al.. (2023). Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia. Journal of Hematology. 12(4). 170–175. 3 indexed citations
3.
Hojjat‐Farsangi, Mohammad, Ann Svensson, Jeanette Lundin, et al.. (2023). A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells. Blood. 142(Supplement 1). 5716–5716. 1 indexed citations
4.
Petris, Luigi De, Parviz Kokhaei, Georgios Z. Rassidakis, et al.. (2023). A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells. Pharmaceutics. 15(4). 1148–1148. 8 indexed citations
5.
Axelsson, Per, Fredrik Ellin, Christian Kjellander, et al.. (2023). Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation‐wide real‐world report on consecutively identified patients. European Journal Of Haematology. 111(5). 715–721. 5 indexed citations
6.
Bogdanović, Gordana, Marcus Buggert, Yu Gao, et al.. (2021). Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Leukemia. 36(2). 476–481. 23 indexed citations
7.
Jones, Jeffrey A., Anthony R. Mato, Steven Coutré, et al.. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology. 182(4). 504–512. 32 indexed citations
8.
Johansson, Hemming, Jenny Klintman, Eva Kimby, et al.. (2018). First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica. 104(4). 797–804. 28 indexed citations
9.
10.
Andersson, Per‐Ola, Karin Karlsson, Claes Karlsson, et al.. (2017). Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program. Blood. 130. 5353. 2 indexed citations
11.
Hojjat‐Farsangi, Mohammad, Amir Hossein Daneshmanesh, Fariba Mozaffari, et al.. (2017). First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells. Blood. 130. 4320–4320. 1 indexed citations
12.
Mellstedt, Håkan, Mohammad Hojjat‐Farsangi, Amir Hossein Daneshmanesh, et al.. (2016). First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor. Annals of Oncology. 27. vi530–vi530. 3 indexed citations
13.
Österborg, Anders, Andrey Zaritskey, Sebastian Grosicki, et al.. (2016). Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 57(9). 2037–2046. 20 indexed citations
14.
Struemper, Herbert, Mark Sale, Bela Patel, et al.. (2014). Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. The Journal of Clinical Pharmacology. 54(7). 818–827. 22 indexed citations
15.
Aapro, Matti, Anders Österborg, Pere Gascón, Heinz Ludwig, & Yves Béguin. (2012). Anaemia and cancer: oral or intravenous iron?. Open Repository and Bibliography (University of Liège). 1 indexed citations
16.
Rieger, Michael A., Anders Österborg, Ruth Pettengell, et al.. (2010). Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Annals of Oncology. 22(3). 664–670. 139 indexed citations
17.
Mozaffari, Fariba, C. Lindemalm, Aniruddha Choudhury, et al.. (2008). Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunology Immunotherapy. 58(1). 111–120. 26 indexed citations
18.
Österborg, Anders, et al.. (2000). Idiotype Immunity (Natural and Vaccine-induced) in Early Stage Multiple Myeloma. Acta Oncologica. 39(7). 797–800. 12 indexed citations
19.
Mellstedt, Håkan, Jan Fagerberg, & Anders Österborg. (1999). Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man. European Journal of Cancer. 35. S29–S32. 8 indexed citations
20.
Grünewald, Johan, et al.. (1991). Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood. 77(8). 1776–1780. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eva Kimby Breakdown of academic impact, for papers by Alessandro Pileri Breakdown of academic impact, for papers by Steven Le Gouill Breakdown of academic impact, for papers by Dominique Bordessoule Breakdown of academic impact, for papers by Grzegorz S. Nowakowski Breakdown of academic impact, for papers by Timothy G. Call Breakdown of academic impact, for papers by Jorge J. Castillo Breakdown of academic impact, for papers by David A. Rizzieri Breakdown of academic impact, for papers by Michele Ghielmini Breakdown of academic impact, for papers by Pellegrino Musto
Rankless by CCL
2026